Search

Your search keyword '"Vullo, V"' showing total 1,205 results

Search Constraints

Start Over You searched for: Author "Vullo, V" Remove constraint Author: "Vullo, V"
1,205 results on '"Vullo, V"'

Search Results

51. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

52. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy

53. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

54. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy

55. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

56. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

57. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients

58. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial

59. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

61. Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter?

63. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

65. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART

66. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

67. Drop in CD4+ counts below 200 cells/µL after reaching (or starting from) values higher than 350 cells/µL in HIV‐infected patients with virological suppression

69. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

73. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus

74. Effectiveness and safety of cobicistat-boosted darunavir-based antiretroviral treatment in an Italian observational cohort: the TMC114FD1HTX4003 (STORE.) study

75. MICROBIOTA COMPOSITION, METABOLIC PROFILES AND INFLAMMATORY HOST RESPONSE AFTER FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION. DOES PROTEOBACTERIA ABUNDANCE PREDICT THE RESPONSE TO FMT?

76. Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015

77. Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)

78. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

79. Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?

80. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

85. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

86. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

87. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

91. Clinical, epidemiological and virological features of acute hepatitis B in Italy

92. Key questions in antiretroviral therapy: Italian Consensus Workshop (2005)

95. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

96. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

97. Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort

98. Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy

Catalog

Books, media, physical & digital resources